[Influenza A, pregnancy and neuraminidase inhibitors].
Following the explosion of the influenza A pandemic (H1N1) during the first semester of 2009, oseltamivir and zanamivir were used as the treatment of choice in the absence of rigorous clinical studies demonstrating their efficacy in the treatment and prophylaxis of this disease. Knowledge of seasonal influenza, flu pandemics and particularly the H1N1, which produces more severe infection and a higher mortality rate during pregnancy, led to the use of antiviral treatment despite the scarcity of clinical studies on their efficacy and effectiveness, mainly due to the influence of the media. This study reviewed the experimental and clinical studies performed on the safety of oseltamivir and zanamivir in pregnancy. Likewise, the recommendations made by the different health care and governmental authorities as well as other institutions and scientific and health care organizations on the therapeutic management and prophylaxis of influenza A 2009 in pregnant women were reviewed.
Montané
Eva
E
Servicio de Farmacología Clínica, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, España. emontane.germanstrias@gencat.cat
Lecumberri
Josep
J
Pedro-Botet
María Luisa
ML
D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001315:Australia; D002487:Centers for Disease Control and Prevention, U.S.; D004353:Drug Evaluation, Preclinical; D004363:Drug Utilization / Q000706:statistics & numerical data; D005060:Europe; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000201:enzymology; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009520:New Zealand; D053139:Oseltamivir / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D058873:Pandemics; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011256:Pregnancy Outcome; D018570:Risk Assessment; D014481:United States; D014764:Viral Proteins / Q000037:antagonists & inhibitors*; D014944:World Health Organization; D053243:Zanamivir / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000998:Antiviral Agents; D014764:Viral Proteins; D053139:Oseltamivir; C487630:NA protein, influenza A virus; D009439:Neuraminidase; D053243:Zanamivir